Novel Coronavirus Information Center

中文资源 (Chinese-language resources)

Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).

All resources are free to access and include guidelines for clinicians and patients.

See our directory of all Elsevier's COVID-19 resources

For researchers

Under the Research tab, you will find a selection of the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made related articles and book chapters free to access on ScienceDirect.

View free articles on ScienceDirect

These articles are also available to download over FTP with rights for full text and data mining, re-use and analyses for as long as needed.

• Server address: coronacontent.np.elsst.com
• Protocol: sftp (SSH File Transfer Protocol)
• Username: public
• Password: beat_corona

You will need to use FTP client software such as Cyberduck or WinSCP to access the FTP server.

Download full text for data mining

For clinicians

Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared resources.

For patients

In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.

Share your feedback to help us improve our Novel Coronavirus Information Center. And if you experience any accessibility problems with the site or content, please contact accessibility@elsevier.com.

Clinical information

In this section, you can find the following resources:

• Guidelines: including new NIH and NICE guidelines; COVID-19 guidance on testing, drug therapy, ventilators, PPE, cardiovascular medicine and anesthesiology; and videos on medical procedures.
• Elsevier Clinical Solutions: Clinical Overviews on ClinicalKey, Clinical Skills for Nursing, Interprofessional Care Plans and patient engagement resources
• Mental and behavioral health: Guidance for anxiety and depression, including Patient Engagement videos

Elsevier COVID-19 Healthcare Hub

Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.

New book

Jie-Ming Qu, Bin Cao and Rong-Chang Chen: Covid-19: The Essentials of Prevention and Treatment (Elsevier, Oct 2020)

Mental and behavioral health

With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's COVID-19 Healthcare Hub.

Anxiety resources

Anxiety screening tool

Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Clinical Skills

• Anxiety – Adults
• Anxiety: Adolescents
• Generalized Anxiety Disorder
• Generalized Anxiety Disorder Management

Clinical Overviews

• Generalized Anxiety Disorder

Interprofessional Care Planning

• Inpatient Anxiety – Adult
• Inpatient Anxiety – Pediatric

Clinical eLearning

• Caring for the patient with General Anxiety Disorder

Patient Education

• Living with Anxiety
• Stress, Adult
• Coping with Anxiety, Teen
• Managing Stress, Teen
• Mindfulness-Based Stress Reduction

Depression resources

Depression screening tool

Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.

Clinical Skills

• Depression
• Depression in Adolescent Patients
• Depression in Older Adult Patients

Clinical Overviews

• Major Depressive Disorder

Patient Education

• Living with Depression
• Supporting Someone with Depression
• Depression Screening
• Coping with Depression, Teen
• How to Help Your Child Cope with Depression

Related stories by Elsevier book authors

Chinese-language resources

Research

In this section, you can find the following resources:

• Journal articles, including coronavirus hubs by The Lancet and Cell Press
• Early-stage research (preprints on SSRN)
• Infographic: global research trends in infectious disease
• Interactive map: global disease outbreak experts

Related articles freely available on ScienceDirect

Elsevier has made coronavirus-related articles freely available for as long as is necessary, commencing in February 2020.

The Lancet Coronavirus Hub

The Lancet's Coronavirus hub page brings together new coronavirus content from The Lancet journals as it is published.

Cell Press Coronavirus Resource Hub

On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find  content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.

1Science Coronavirus Research Repository

1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.

Centre d’information sur le nouveau coronavirus

This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.

You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.

Early-stage research: preprints on SSRN

Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.” SSRN , Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.

View coronavirus research on SSRN

Top 10 SSRN downloads of the week*

1. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study 9,063
2. Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1 7,435
3. Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia 432
4. Recommendations for the Recognition, Diagnosis, and Management of Patients with Post COVID-19 Condition ('Long COVID'): A Delphi Study 367
5. Decreased Infectivity Following BNT162b2 Vaccination 144
6. Myopia Progression in Children During COVID-19 Home Confinement in Argentina 114
7. 6-Month Follow Up of Hospitalised COVID-19 Patients: A Nationwide Cohort Study of 8679 Patients in Germany 80
8. Behavioral Nudges Increase COVID-19 Vaccinations: Two Randomized Controlled Trials 74
9. Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial 52
10. Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study) 28

* Calculated on Thursday, April 15, 2021

Infographic: Global research trends

Interactive map: global coronavirus experts

This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~96,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: April 10, 2021)

Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

R&D tool to capture clinical trial data is free for researchers studying COVID-19

Elsevier recently launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at covid19@elsevier.com and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release

Gender and COVID-19 Group on Mendeley

This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References - articles, preprints, news articles, blog posts, magazine articles, reports, etc - include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.

COVID-19 drug therapy — updated on October 26

Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.

Drug information from Elsevier's R&D Solutions

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:

• 121 drugs and natural products successfully used against previous coronavirus infections including SARS. This list was generated using Elsevier's Pathway Studio.
• 393 substances that interact with 25 targets related to 6 target species including SARS coronavirus, Middle East respiratory syndrome coronavirus, human Middle East respiratory syndrome coronavirus, Human coronavirus 229E, Coronaviridae and Coronavirinae, with normalized affinity value > 6. This list was generated using Elsevier’s Reaxys Medicinal Chemistry.
• Autophagy is a cellular recycling process, whereby cells eliminate damaged or diseased components in order to regenerate and build new healthier cells; thus, viruses are usually identified and disposed of in this way. Would it be possible to induce the autophagy process and limit the viral infection by using some substances? Pathway Studio provides a list of 406 compounds that have been reported inhibiting autophagy pathway, and their related references as well as a list of 802 compounds that have activating roles in autophagy.

Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability

The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper

Pure portal: Discover research collaborators and institutions globally

Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.

Additional information and examples

Public health

Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.

Research!America webinar

COVID-19 treatments exemplify the significance of public-private sector R&D but haven't received the same attention as vaccines, creating possible knowledge gaps. This free Research!America webinar — Science v Covid-19: Promising Treatments Explained (recorded on Feb 25, 2021) — features expert panelists including Dr Rajesh T. Gandhi Infectious Diseases Society of America; Dr James L. Madara, CEO and EVP American Medical Association (AMA); Denise Brooks-Williams, Senior VP and CEO North Market, Henry Ford Health System; Dr Michael Ybarra, MD, VP and Chief of Medical Affairs, PhRMA. Register to view on demand

Free on demand: 14th Vaccine Congress Online Edition

Elsevier's 14th Vaccine Congress – Online Edition: Combatting the threat of Covid-19, held in September 2020, featured leading experts in vaccinology sharing their knowledge on the current developments and challenges we face. Sessions are available free on demand. Register here

Dr. Fauci features Cell paper in Congressional hearing

Studies to improve face masks and disinfect the air

• In a new article in Materials Today Physics, researchers describe their air disinfection system to control the spread of COVID-19, for which they filed a provisional patent application: Catching and killing of airborne SARS-CoV-2 to control spread of COVID-19 by a heated air disinfection system (July 7, 2020)

• In Open Ceramics, researchers describe a sputtered antimicrobial/virucidal silver nanoclusters/silica composite coating to significantly improve the protection capacity of face masks while also being suitable for coating air filters and other surfaces: Virucidal effect against Coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating (June 6, 2020)

Special issue: Bioaerosol and infectious diseases

This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.

COVID-19 Data Insights Map by LexisNexis Risk Solutions

By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map

Progress in Disaster Science: COVID-19 Special Collection

Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection

Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"

The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section

COVID-19 podcasts and webinars by CIDRAP

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

More public health resources

• CDC vaccine guidance
• Disaster Epidemiology and Surveillance, Chapter 27, Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health, 5th Edition (Elsevier, 2020)
• Impacts on Society and Economy (OECD)
• Interactive map showing global spread of COVID-19 (WHO)
• Interactive map shows global spread of the virus (Johns Hopkins CSSE)
• Guidance for businesses and employers (CDC)
• Travel precautions (CDC)
• Information and updates (CDC)
• Novel coronavirus advice for the public (WHO)
• Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance (WHO)
• National Genomic Data Center (China) 2019 nCoV Resource Center (新型冠状病毒信息库)

Official coronavirus guidance from various countries:

Argentina | Australia | Canada | Chile | China | Colombia | France | Germany | Mexico | Peru | Singapore | Spain | UK | US

• Sources of updated information in the EU/EEA countries
• Panamerican Health Organization (Latin American branch of the WHO)

Patient resources

عدوى فيروس كورونا المستجد (patient education in Arabic)

عدوى فيروس كورونا المستجد

Elsevier's Patient Access Program for research

With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing patientaccess@elsevier.com. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more

COVID-19 podcasts and webinars

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

More resources

• Novel coronavirus advice for the public (WHO)
• Travel precautions (CDC)
• See our Patient Education resources under Mental & Behavioral Health

Usage notice

Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).

This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.